$VC

Visteon (NASDAQ:VC) Price Target Lowered to $134.00 at Wells Fargo & Company

Wells Fargo lowered its Visteon (NASDAQ:VC) price target to $134 from $137 and kept an “overweight” rating, citing potential upside of 26.62% versus the prior close, according to Benzinga. Other firms adjusted targets. Visteon last reported Q2 EPS of $1.91 (vs $2.21 expected) on $960M revenue.

Original reporting
Published Jul 24, 2026, 3:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 24, 2026, 10:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Visteon (NASDAQ:VC) Price Target Lowered to $134.00 at Wells Fargo & Company — source image
Decision brief

The 30-second read

$VCNeutralLow
01

Why it matters

For traders, the actionable signal is the modest valuation reset from Wells Fargo, not a new fundamental event. The broader context includes a recent earnings miss and ongoing capital return via an accelerated share repurchase program mentioned in the news summary.

02

Market read

A small price-target reduction with an unchanged overweight rating suggests limited incremental risk, but it may slightly temper upside expectations into the next catalyst.

03

What to watch

The article also references the prior quarter’s EPS miss and insider selling; those may matter more for near-term trading than the incremental $3 target trim.

Relevance 4/10Novelty 4/10Timing: after-hours/Friday research note coverage, ahead of next earnings/guidance updates

Background

The piece summarizes a Wells Fargo research note that reduced Visteon’s price objective, alongside a recap of recent earnings and other broker target changes.

Company-level read

Ticker impact

$VCNeutralMedium confidence
Context

Wells Fargo cut its Visteon price target to $134 from $137 while keeping an “overweight” rating, signaling a modest valuation reset.

Expected impact

Near-term downside bias versus prior target, but limited incremental impact given the “overweight” stance and small magnitude of the cut.

Evidence & confidence

The article’s only fresh, company-specific decision is the Wells Fargo target reduction; other broker notes are mixed but not described as new catalysts beyond target/rating adjustments.

Market effects

Limited read-across to auto-parts suppliers, since the update is a single-name valuation adjustment rather than a sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

The target cut could be interpreted as analysts de-risking near-term fundamentals after the recent EPS miss, even if the rating remains overweight.

Key entities

  • Visteon

    NASDAQ-listed automotive electronics supplier; subject of the Wells Fargo price-target reduction and recent earnings recap.

  • Wells Fargo & Company

    Issued the research note lowering Visteon’s price target to $134 while maintaining an “overweight” rating.

Related articles

Med

Visteon Corporation Q3 2026 Earnings Call Summary

Visteon Corporation reported Q3 2026 earnings, highlighting 10 percentage points of market outperformance despite a 5% decline in vehicle production. The company addressed $77 million in warranty charges and managed inflation in PCBs. For 2027, Visteon anticipates $500 million in incremental costs and aims to maintain EBITDA targets through customer recoveries. China sales are expected to grow in Q4 2026, driven by high-performance compute launches.

Med

Visteon (VC) Q3 2026 Earnings Call Transcript

Visteon (VC) reported Q3 2026 earnings, highlighting a $200M share repurchase and sales growth despite market challenges. Sales grew in Americas, Europe, and Asia (excluding China), with China sales expected to recover in Q4. The company launched 21 new products, including high-value cockpit technologies, and secured $1B in new business bookings, targeting $6B for the year. Strategic wins include programs with Toyota, Maruti Suzuki, and Tata Motors.

$VCMedAI 8/10

What Visteon (VC) Said on Its Q3 Earnings Call

Visteon (VC) reported Q3 earnings, noting regional sales trends and product launches. Sales rose 14% in Asia excluding China, but faced challenges in the Americas and China. The company expects China sales to grow in Q4 with new launches. Visteon launched 21 products and booked $1B in new business, maintaining its $6B annual target. It updated guidance, raising full-year sales to $3.8B-$3.85B but lowering adjusted EBITDA to $370M-$410M. Q4 sales are expected to be $940M, flat YoY.